Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VIR Stock Forecast 2026-2027
$9.40
Current Price
$1.60B
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VIR Price Targets
+219.1%
To High Target of $30.00
+123.4%
To Median Target of $21.00
+70.2%
To Low Target of $16.00
VIR Price Momentum
-5.6%
1 Week Change
+1.1%
1 Month Change
+71.2%
1 Year Change
+55.9%
Year-to-Date Change
-19.4%
From 52W High of $11.66
+126.2%
From 52W Low of $4.16
📊 TOP ANALYST CALLS
Did VIR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vir Biotechnology is one of their latest high-conviction picks.
Latest VIR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, VIR has a bullish consensus with a median price target of $21.00 (ranging from $16.00 to $30.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $9.40, the median forecast implies a 123.4% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VIR Analyst Ratings
10
Buy
0
Hold
0
Sell
VIR Price Target Range
Low
$16.00
Average
$21.00
High
$30.00
Current: $9.40
Latest VIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2026 | Morgan Stanley | Michelle Gilson | Overweight | Maintains | $27.00 |
| Jun 3, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 25, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 24, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Feb 24, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Feb 24, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 9, 2026 | Needham | Buy | Reiterates | $N/A | |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 3, 2025 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Aug 27, 2025 | B of A Securities | Buy | Upgrade | $N/A | |
| Jul 11, 2025 | Raymond James | Outperform | Initiates | $N/A | |
| May 22, 2025 | Needham | Buy | Reiterates | $N/A | |
| May 12, 2025 | Needham | Buy | Maintains | $N/A | |
| Apr 17, 2025 | Goldman Sachs | Buy | Maintains | $N/A | |
| Feb 28, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 27, 2025 | Needham | Buy | Reiterates | $N/A | |
| Jan 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Vir Biotechnology Inc. (VIR) Competitors
The following stocks are similar to Vir Biotechnology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vir Biotechnology Inc. (VIR) Financial Data
Vir Biotechnology Inc. has a market capitalization of $1.60B with a P/E ratio of -3.0x. The company generates $65.50M in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is -100.1% quarter-over-quarter, while maintaining an operating margin of +459,241.4% and return on equity of -47.7%.
Valuation Metrics
Market Cap
$1.60B
Enterprise Value
$1.30B
P/E Ratio
-3.0x
PEG Ratio
0.9x
Price/Sales
24.8x
Growth & Margins
Revenue Growth (YoY)
-100.1%
Gross Margin
N/A
Operating Margin
+459,241.4%
Net Margin
+100.0%
EPS Growth
-102.3%
Financial Health
Cash/Price Ratio
+30.0%
Current Ratio
7.1x
Debt/Equity
11.8x
ROE
-47.7%
ROA
-24.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vir Biotechnology Inc. (VIR) Business Model
About Vir Biotechnology Inc.
What They Do
Develops immune-based therapies for infectious diseases and cancer.
Business Model
Vir Biotechnology operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of innovative therapies that harness the immune system. The company generates revenue through partnerships, grants, and potential product sales stemming from its advancing pipeline of treatments, particularly targeting serious infectious diseases and cancers.
Additional Information
Founded in 2016 and based in San Francisco, Vir Biotechnology employs advanced technologies like its next-generation antibody platform and PRO-XTEN for therapeutic innovations. Its lead programs are in critical trial phases, and the company's research pipeline includes a variety of diseases, indicating a robust commitment to addressing unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
367
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Country
United States
IPO Year
2019
Website
www.vir.bioVir Biotechnology Inc. (VIR) Latest News & Analysis
Latest News
Quick Summary
Vir Biotechnology is set for key clinical trial updates from its ECLIPSE program in hepatitis delta and T-cell engagers in oncology, with data from VIR-5818 expected in H2'26.
Why It Matters
Vir Biotechnology's upcoming clinical trial results and partnerships could significantly impact its stock valuation and market position in oncology and hepatitis treatments, influencing investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Vir Biotechnology appointed Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026, enhancing its leadership at a critical time.
Why It Matters
Timothy Coughlin's appointment to Vir Biotechnology's Board signals potential strategic shifts, impacting governance and future financial performance, which could influence stock value and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology will present Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta at EASL Congress 2026 in Barcelona, May 27-30, 2026.
Why It Matters
Positive Phase 2 trial data for Vir Biotechnology's hepatitis delta treatment could drive stock value and investor interest, indicating potential market growth and therapeutic advancements.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology is rated a buy due to a strong cash position and late-stage pipeline. Its drugs target a large market, and a partnership with Astellas secures funding until 2028.
Why It Matters
Vir Biotechnology's strong cash position and late-stage pipeline enhance its growth potential, while partnerships and market opportunities reduce dilution risk, making it an attractive investment prospect.
Source: Seeking Alpha
Market Sentiment:
Positive
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2 months ago
Quick Summary
Vir Biotechnology, Inc. (VIR) presented at the Bank of America Global Healthcare Conference, discussing its latest developments and strategies.
Why It Matters
Vir Biotechnology's presentation may signal advancements in its research or pipeline, impacting its stock performance and attracting investor interest in biotech developments.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology, Inc. (VIR) held its Q1 2026 earnings call, providing updates on financial performance and company progress. Further details on earnings and projections were discussed.
Why It Matters
The earnings call reveals Vir Biotechnology's financial performance and strategic direction, impacting stock valuation and investor sentiment regarding future growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VIR Stock
What is Vir Biotechnology Inc.'s (VIR) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Vir Biotechnology Inc. (VIR) has a median price target of $21.00. The highest price target is $30.00 and the lowest is $16.00.
Is VIR stock a good investment in 2027?
According to current analyst ratings, VIR has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VIR stock?
Wall Street analysts predict VIR stock could reach $21.00 in the next 12 months. This represents a 123.4% increase from the current price of $9.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vir Biotechnology Inc.'s business model?
Vir Biotechnology operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of innovative therapies that harness the immune system. The company generates revenue through partnerships, grants, and potential product sales stemming from its advancing pipeline of treatments, particularly targeting serious infectious diseases and cancers.
What is the highest forecasted price for VIR Vir Biotechnology Inc.?
The highest price target for VIR is $30.00 from at , which represents a 219.1% increase from the current price of $9.40.
What is the lowest forecasted price for VIR Vir Biotechnology Inc.?
The lowest price target for VIR is $16.00 from at , which represents a 70.2% increase from the current price of $9.40.
What is the overall VIR consensus from analysts for Vir Biotechnology Inc.?
The overall analyst consensus for VIR is bullish. Out of 2 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are VIR stock price projections?
Stock price projections, including those for Vir Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:25 AM UTC